Endogenous blood maximal interferon-γ production may predict response to interferon-γ 1β treatment in patients with idiopathic pulmonary fibrosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 26, Issue 1, 2009, Pages 64-68

  Luppi, Fabrizio ^a   Losi, M ^a   D'Amico, R ^a   Fabbri, L M ^a   Richeldi, L ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

ELISpot; IPF; Prognosis; Therapy

Indexed keywords

AZATHIOPRINE; GAMMA INTERFERON; GAMMA1B INTERFERON; PREDNISONE; RECOMBINANT GAMMA INTERFERON;

ADULT; AGED; ARTERIAL OXYGEN SATURATION; ARTHRALGIA; ARTICLE; BLOOD SAMPLING; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FEVER; DRUG INDUCED HEADACHE; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FIBROSING ALVEOLITIS; HUMAN; INJECTION SITE PAIN; LOW DRUG DOSE; LUNG FUNCTION; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL;

AGED; BIOLOGICAL MARKERS; DRUG ADMINISTRATION SCHEDULE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; INTERFERON-GAMMA, RECOMBINANT; ITALY; LUNG; MALE; MIDDLE AGED; OXYGEN; PILOT PROJECTS; PREDICTIVE VALUE OF TESTS; RESPIRATORY FUNCTION TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349248013     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174 (7): 810-816 (Pubitemid 44511663)
2. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161 (2 Pt 1): 646-664
3. Rudd R, Prescott RJ, Chalmers JC, Johnston ID. British Thoracic Society study of cryptogenic fibrosing alveolitis: response to treatment and survival. Thorax 2006. (Pubitemid 46101768)
4. Walter N, Collard HR, King TE, Jr. Current perspectives on the treatment of idiopathic pulmonary fibrosis. Proc Am Thorac Soc 2006; 3 (4): 330-338
5. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med 1999; 341 (17): 1264-1269 (Pubitemid 29489741)
6. Raghu G, Brown KK, Bradford WZ, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med 2004; 350 (2): 125-133 (Pubitemid 38056223)
7. Bajwa EK, Ayas NT, Schulzer M, Mak E, Ryu JH, Malhotra A. Interferon-gamma1b therapy in idiopathic pulmonary fibrosis: a metaanalysis. Chest 2005; 128 (1): 203-206 (Pubitemid 40994474)
8. Honore I, Nunes H, Groussard O, et al. Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis. Am J Respir Crit Care Med 2003; 167 (7): 953-957 (Pubitemid 36408159)
9. Kalra S, Utz JP, Ryu JH. Interferon gamma-1b therapy for advanced idiopathic pulmonary fibrosis. Mayo Clin Proc 2003; 78 (9): 1082-1087 (Pubitemid 37055652)
10. Strieter RM, Starko KM, Enelow RI, Noth I, Valentine VG. Effects of interferon-gamma 1b on biomarker expression in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 170 (2): 133-140 (Pubitemid 38925158)
11. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science 1996; 272 (5258): 54-60. (Pubitemid 26110754)
12. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002; 165 (2): 277-304.
13. Wood KJ, Sawitzki B. Interferon gamma: a crucial role in the function of induced regulatory T cells in vivo. Trends Immunol 2006; 27 (4): 183-187
14. Schroecksnadel K, Fuchs D. Interferon-gamma for counteracting Tcell activation. Trends Immunol 2006; 27 (9): 398.
15. Fuchs D, Shearer GM, Boswell RN, et al. Increased serum neopterin in patients with HIV-1 infection is correlated with reduced in vitro interleukin-2 production. Clin Exp Immunol 1990; 80 (1): 44-48 (Pubitemid 20113403)
16. Fuchs D, Malkovsky M, Reibnegger G, Werner ER, Forni G, Wachter H. Endogenous release of interferon-gamma and diminished response of peripheral blood mononuclear cells to antigenic stimulation. Immunol Lett 1989; 23 (2): 103-108 (Pubitemid 20022932)
17. Fahey JL, Taylor JM, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med 1990; 322 (3): 66-72. (Pubitemid 20036390)
18. Wirleitner B, Neurauter G, Schrocksnadel K, Frick B, Fuchs D. Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem 2003; 10 (16): 1581-1591 (Pubitemid 36896559)
19. Homolka J, Ziegenhagen MW, Gaede KI, Entzian P, Zissel G, Muller-Quernheim J. Systemic immune cell activation in a subgroup of patients with idiopathic pulmonary fibrosis. Respiration 2003; 70 (3): 262-269 (Pubitemid 36980770)
20. Lilford RJ, Thornton JG, Braunholtz D. Clinical trials and rare diseases: a way out of a conundrum. BMJ 1995; 311 (7020): 1621-1625 (Pubitemid 26002712)